AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcgammaR-binding domain to reduce FcgammaR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [177Lu] radiolabeled AKIR001, namely [177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma[1].
